After months of a total blockade of Gaza by the Israeli government and increasingly dire exasperated warnings of starvation from humanitarian groups and aid groups, the Trump administration in partnership I think with the Israeli government has come up with this new way of delivering aid into Gaza just in the last say 6 weeks. So rather than Israel just lifting the blockade and letting groups like the UN and other NOS's that have delivered aid in Gaza for years, what's happened is the Trump administration b ...

In the sea of red, energy is the only sector uh on top today with oil prices moving sharply higher on the heels of of Israel's air strikes against Iran. Crude's still up about 7%. Pipa Stevens has a closer look at Iran's energy complex and why the state of Hormuz Pipa is going to be key here.So Kelly, oil's next move really depends here on how Iran responds to the attacks. Now the country itself is not a major supplier. They export about 1.7% million barrels per day with more than 90% of those exports comin ...

months. Pipa Stevens is tracking all of that action. A lot of other commodities as well.Uh Pipa, that's right, David. So, oil is still up 6%, but as you said, well off the highs of the session after WTI at one point jumped 14% overnight, underlining the fact that so far no oil supply has actually been disrupted with several firms saying prices cannot sustain these levels unless barrels actually come off the market. The focus now turns to Iran's response since that is likely what will dictate oil's next move ...

[Music] The maritime zone of the coast of Gaza is close to naval traffic as part of a legal naval blockade. If you wish to deliver humanitarian aid to the Gaza Strip, you are able to do so through the port of Ashdod via the established channels and distribution centers. Everyone phones need to go. Phones need to go in the water. In the water.Okay. Okay. [Music]. ...

Corvus Pharmaceuticals (CRVS) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Alright. Welcome, everyone, to Jefferies twenty twenty five, global health care conference. My name is Roger Song, one of the senior analysts covering semi cap biotech in The US. It's my pleasure to introduce our next printing company covers. We have the CEO, Rich Miller. Speaker1 Thank you Roger and good morning everyone. I want to thank Jeffries for the invitation to the healthcare conference and thank you all for attending. ...

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARMINSTER, Pa., ...

Core Viewpoint - Bicara Therapeutics Inc. is advancing its lead product, ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, showing promising results in treating solid tumors, particularly in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma [1][2][9] Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with ficerafusp alfa as its lead program [9] - The company aims to address significant unmet needs in cancer treatment, particularly in patients with advanced or metastatic diseases [4][9] Product Development - Ficerafusp alfa is a first-in-class bifunctional antibody that combines an EGFR-directed monoclonal antibody with a TGF-β binding domain, potentially enhancing anti-tumor activity by targeting both cancer cell survival and immunosuppressive signaling [7][9] - The drug is currently being evaluated in pivotal Phase 2/3 clinical trials for first-line recurrent/metastatic head and neck squamous cell carcinoma [8] Clinical Data Highlights - Recent presentations at the AACR Annual Meeting 2025 showcased data supporting ficerafusp alfa's ability to block TGF-β signaling, which may prevent resistance mechanisms in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma [2][3] - In a Phase 1/1b trial for second-line metastatic cutaneous squamous cell carcinoma, ficerafusp alfa demonstrated an overall response rate of 30.4% and a clinical benefit rate of 82.6%, with a median progression-free survival of 7.0 months [3][4] - The drug also showed potential in reversing acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant lung cancer, indicating its broad therapeutic potential [5][11] Market Context - Cutaneous squamous cell carcinoma is the second most common skin cancer, with rising incidence highlighting the need for effective treatment options, especially for patients who progress on anti-PD-1 therapies [4][6] - The lack of approved second-line therapies for patients with advanced or metastatic cutaneous squamous cell carcinoma underscores the importance of ficerafusp alfa's development [4][6]